Randomized trial · people
Retatrutide: HbA1c down up to 1.94% in TRANSCEND-T2D-1
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In adults with type 2 diabetes on diet and exercise alone, all three retatrutide doses lowered HbA1c and body weight more than placebo over 40 weeks.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 537
- Published
- 2026
- Journal
- Lancet
What they tested
The researchers asked whether retatrutide as the only diabetes medicine lowers HbA1c and body weight in adults whose type 2 diabetes stayed above target despite diet and exercise.
How the study was done
A randomized, double-blind, placebo-controlled phase 3 trial in 537 adults with type 2 diabetes, run across 48 clinics in three countries. Each person was assigned to one of three retatrutide doses (the 4 mg, 9 mg, and 12 mg arms) or to placebo (a dummy shot), given once a week under the skin for 40 weeks.

Model. Individual results vary.
What they found
HbA1c (a 3-month average of blood sugar) changed by -1.69% in the 4 mg arm, -1.86% in the 9 mg arm, and -1.94% in the 12 mg arm, compared with -0.81% on placebo. Against placebo, the differences were -0.88%, -1.04%, and -1.12%, all p<0.0001. Body weight changed by -11.5%, -13.9%, and -15.3% across the three retatrutide arms, compared with -2.6% on placebo. The most common side effects were mostly mild to moderate stomach and gut problems that eased over time; 2-5% on retatrutide and 0% on placebo stopped treatment because of side effects, no severe low blood sugar was seen, and the 2 deaths, both in the 4 mg arm, were judged unrelated to the drug.
What it doesn’t show
The trial lasted 40 weeks, compared retatrutide only with placebo rather than other diabetes drugs, and included people with fairly recent diabetes (mean 2.5 years) using no other diabetes medicine. It was funded by Eli Lilly and Company.
The paper
Bajaj et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. 2026.
The compound
More studies on Retatrutide
- Retatrutide: systolic blood pressure down 6.79 mmHg in meta-analysisMeta-analysis · people · 2026
- Retatrutide: top odds of 15% or more weight loss across 19 trialsMeta-analysis · people · 2025
- Retatrutide: non-HDL cholesterol down up to 26.9% in phase 2 trialsRandomized trial · people · 2026
- Retatrutide: up to 25.0% weight loss at 80 weeks in TRIUMPH-1Randomized trial · people · 2026
- Retatrutide: 26.1% fat mass loss at 36 weeks in type 2 diabetesRandomized trial · people · 2025
- Retatrutide: less hunger and overeating vs placebo at higher dosesRandomized trial · people · 2025
- Every study on Retatrutide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.